BioLineRx Ltd. Stock price

Equities

BLRX

IL0011015182

Biotechnology & Medical Research

Market Closed - TEL AVIV STOCK EXCHANGE 11:24:58 2024-03-28 am EDT 5-day change 1st Jan Change
28 ILa +0.36% Intraday chart for BioLineRx Ltd. -6.35% -26.70%
Sales 2023 4.8M 1.77B Sales 2024 * 14.36M 5.28B Capitalization 82.97M 30.51B
Net income 2023 -60M -22.06B Net income 2024 * -47M -17.28B EV / Sales 2023 23.9 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 5.78 x
P/E ratio 2023
-1.76 x
P/E ratio 2024 *
-3.82 x
Employees 49
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production CI
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer CI
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®? CI
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease CI
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director CI
Transcript : BioLineRx Ltd., Q3 2023 Earnings Call, Nov 20, 2023
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug MT
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment CI
BioLineRx Ltd. announced that it has received $14.6 million in funding CI
BioLineRx Says Pilot Phase of Combination Trial With Motixafortide in First-Line Pancreatic Cancer Yields 'Encouraging' Data MT
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer CI
HC Wainwright Raises BioLineRx's Price Target to $21 From $19, Maintains Buy Rating MT
More news
1 day+0.36%
1 week-6.35%
Current month-12.23%
1 month-11.11%
3 months-27.08%
6 months-42.27%
Current year-26.70%
More quotes
1 week
27.10
Extreme 27.1
33.50
1 month
27.10
Extreme 27.1
34.90
Current year
26.80
Extreme 26.8
40.60
1 year
18.80
Extreme 18.8
70.00
3 years
13.40
Extreme 13.4
136.00
5 years
13.40
Extreme 13.4
162.70
10 years
13.40
Extreme 13.4
1 059.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 09-05-23
Director of Finance/CFO 48 08-12-31
Chief Tech/Sci/R&D Officer - 17-08-31
Members of the board TitleAgeSince
Director/Board Member 77 14-02-23
Director/Board Member 85 10-08-31
Director/Board Member 66 09-12-31
More insiders
Date Price Change Volume
24-03-28 28 +0.36% 866,531
24-03-27 27.9 -4.78% 3,449,825
24-03-26 29.3 -11.75% 4,642,403
24-03-25 33.2 +11.04% 2,148,510
24-03-21 29.9 +2.75% 604,346

Delayed Quote TEL AVIV STOCK EXCHANGE, March 28, 2024 at 11:24 am EDT

More quotes
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
More about the company
  1. Stock
  2. Equities
  3. Stock BioLineRx Ltd. - TEL AVIV STOCK EXCHANGE